Compare Neurocrine Biosciences Inc (NBIX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Neurocrine Biosciences Inc trades at $155.7 (market cap $15.77B), while Vanguard Intermediate Term Corporate Bond ETF trades at $80.31. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | VCIT | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Fixed Income |
52-Week High | $185.50 | $84.82 |
52-Week Low | $123.10 | $80.31 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
VCIT trades at $80.46, down 0.09% on the day, with technical indicators showing a bearish trend from moving averages but bullish momentum from oscillators like the RSI. Recent news highlights institutional buying and favorable comparisons to peers due to its low 0.03% expense ratio and 4.8% yield, positioning it as a cost-effective intermediate-term corporate bond ETF.
The outlook for VCIT is supported by strong income appeal and institutional interest, but risks include interest rate sensitivity and market volatility. Analysts view it positively for its yield and low costs, though the bearish technical trend warrants caution for near-term price movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
